Project Grant R01CA287731
Award Date
9/13/24
Completion Date
8/31/29
Dollars Obligated
$571K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Buffalo, NY 14263, USA
Similar Awards
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $226,504 to the University of Virginia to elucidate the role of B and T cell-enriched immune aggregates in immune surveillance against triple-negative breast cancer (TNBC). The research aims to comprehensively understand the functional state of B and T cells, as well as mutant/tumor cells, in a mouse model of TNBC at both pre-malignant and malignant stages. Additionally, the...
This federal Project Grant award of $107,948.00 from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) supports research to investigate the role of the MALT1 protein in promoting immunosuppression in triple-negative breast cancer (TNBC).
The award recipient, the University of Pittsburgh, will conduct a two-part research project. In Aim 1, the team will analyze how MALT1 protease activity within TNBC cells regulates the tumor immune microenvironment...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), supports a two-pronged approach to target triple-negative breast cancer (TNBC). The $403,686 award, effective June 1, 2024 through May 31, 2026, will enable researchers at Rutgers, The State University of New Jersey to:
Explore the use of a targeted hybrid vector called AAVP to deliver human tumor necrosis factor (TNF) to both TNBC tumor cells and associated...
This $118,912 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research by the University of North Carolina at Chapel Hill (UNC-CH) to characterize and overcome major histocompatibility complex class I (MHC-I)-mediated immune evasion in triple-negative breast cancer (TNBC). The funded research aims to functionally and molecularly examine how MHC-I loss affects TNBC tumor progression and immune cell infiltration, and to evaluate...
This $460,977 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research to identify novel "chemo-neoepitopes" (CNEs) that can be used as immunogens to mobilize tumor-specific CD8+ T cells for immunotherapy against triple-negative breast cancer (TNBC).
The research, conducted by Health Research, Inc. at the Roswell Park Division, aims to: 1) identify candidate CNE peptide sequences generated by...
The National Cancer Institute (NCI) awarded a $616,071 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to The University of Texas Health Science Center at San Antonio (UTHSCSA) to develop novel adenosine receptor inverse agonists for the treatment of metastatic triple negative breast cancer (TNBC). This 5-year grant, which commenced on February 24, 2025, supports research to advance therapeutic interventions for TNBC, an aggressive form of breast cancer that...
This Project Grant award, titled "IMPROVING THE PLATELET-MEDIATED IMMUNE CHECKPOINT INHIBITOR DELIVERY FOR TREATING TRIPLE-NEGATIVE BREAST CANCER", is funded by the National Cancer Institute (NCI) under the Cancer Treatment Research (CFDA 93.395) federal grant program. The $619,764 award, which commences on January 10, 2025 and runs through December 31, 2029, aims to develop new combination immunotherapy strategies to enhance the anti-tumor efficacy against triple-negative breast...
This federal Project Grant award under the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $606,697 to the Augusta University Research Institute, Inc. (doing business as Georgia Health Sciences) to conduct research on suppressing the co-chaperone UNC45A as a novel immunotherapeutic target for treating triple-negative breast cancer (TNBC).
The key products and services to be delivered include:
Characterizing how suppressing UNC45A in TNBC tumors reprograms...
This $622,329 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) is funding research at Virginia Commonwealth University (VCU) to develop an inhibitor called PDZ1i that can prevent metastasis and improve the efficacy of chemotherapy for triple-negative breast cancer (TNBC). The key research objectives include: 1) Formulating the PDZ1i inhibitor for clinical use and characterizing its immunomodulatory effects in suppressing...
This federal Project Grant award, totaling $719,799.00, was provided by the National Cancer Institute (NCI) under its Cancer Biology Research program (CFDA 93.396). The grant aims to investigate the impact of metabolic adaptations on the tumor microenvironment and immune response in metastatic triple-negative breast cancer (TNBC). Key objectives include:
Examining the bifunctional mechanisms by which the metabolic enzyme PFKFB4 regulates TNBC tumor cell plasticity and metastatic competence...